Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2009. The report discloses a notification received from BlackRock, Inc. regarding a major interest in the company's ordinary shares, triggered by the acquisition of the Barclays Global Investors (BGI) business by BlackRock.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
BlackRock, Inc. crossed the 5% voting rights threshold on December 1, 2009. Following the acquisition of BGI, BlackRock's total holding of voting rights increased to 332,238,289 shares, representing 6.40% of the total voting rights.
- Direct Shareholding: 329,124,508 shares (6.34% voting rights).
- Financial Instruments (CFDs): 3,113,781 voting rights (0.06% voting rights).
Outlook, Risks, and Management Commentary
The filing contains no management commentary, financial guidance, or discussion of operational risks. The disclosure is strictly procedural, noting that the threshold crossing was an automatic result of the BGI acquisition by BlackRock.
Key Facts for Investor Verification
- BlackRock, Inc. now holds a 6.40% voting interest in GlaxoSmithKline plc.
- The increase in holdings was driven by the acquisition of Barclays Global Investors (BGI) on December 1, 2009.
- The holding includes both direct shares and Contract for Difference (CFD) instruments.
- This filing does not contain financial performance data for the period.